Patents Assigned to Dharmacon, Inc.
  • siRNA targeting amyloid beta (A4) precursor protein (APP)
    Patent number: 8268985
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APP.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: September 18, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Catenin, Beta-1 (CTNNB1)
    Publication number: 20120220496
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.
    Type: Application
    Filed: May 8, 2012
    Publication date: August 30, 2012
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
    Patent number: 8252755
    Abstract: Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: August 28, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Christina Yamada, Anastasia Khvorova, Rob Kaiser, Emily Anderson, Devin Leake
  • SiRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2)
    Patent number: 8247169
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for DGAT2.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: August 21, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting glucagon receptor (GCGR)
    Patent number: 8236942
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for GCGR.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: August 7, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
    Patent number: 8232385
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: July 31, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting apolipoprotein B (APOB)
    Patent number: 8232386
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: July 31, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Connective Tissue Growth Factor (CTGF)
    Publication number: 20120184463
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF.
    Type: Application
    Filed: February 14, 2012
    Publication date: July 19, 2012
    Applicant: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting kinase insert domain receptor (KDR)
    Patent number: 8222395
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: July 17, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting proto-oncogene MET
    Patent number: 8222396
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MET.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: July 17, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting interleukin-1 receptor-associated kinase 4(IRAK4)
    Patent number: 8217162
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: July 10, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting catenin, beta-1 (CTNNB1)
    Patent number: 8198427
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: June 12, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting spleen tyrosine kinase
    Publication number: 20120135892
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Application
    Filed: December 6, 2011
    Publication date: May 31, 2012
    Applicant: DHARMACON INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe
  • SIRNA TARGETING CATENIN, BETA-1 (CTNNB1)
    Publication number: 20120136144
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.
    Type: Application
    Filed: October 30, 2007
    Publication date: May 31, 2012
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Duplex oligonucleotides with enhanced functionality in gene regulation
    Patent number: 8188060
    Abstract: Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.
    Type: Grant
    Filed: February 10, 2009
    Date of Patent: May 29, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Devin Leake, Barbara Robertson, Annaleen Vermeulen, Christina Yamada
  • Modified Cell Lines for Increasing Lentiviral Titers
    Publication number: 20120083035
    Abstract: The present disclosure provides a method of modifying cells in order to enhance lentiviral titers, cell lines that are modified and modifying reagents. By mediating individual genes and combination thereof, lentiviral titers may be increased.
    Type: Application
    Filed: August 31, 2011
    Publication date: April 5, 2012
    Applicant: DHARMACON, INC.
    Inventors: Katie Jansen Spayd, Jon Karpilow, John K. Wakefield
  • siRNA targeting connective tissue growth factor (CTGF)
    Patent number: 8138329
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: March 20, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Apolipoprotein B (APOB)
    Publication number: 20120065250
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.
    Type: Application
    Filed: October 27, 2011
    Publication date: March 15, 2012
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • METHODS AND COMPOSITIONS FOR SELECTING SIRNA OF IMPROVED FUNCTIONALITY
    Publication number: 20120052487
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Application
    Filed: September 14, 2004
    Publication date: March 1, 2012
    Applicant: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting VEGFA and Methods for Treatment In Vivo
    Publication number: 20120029051
    Abstract: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.
    Type: Application
    Filed: July 26, 2011
    Publication date: February 2, 2012
    Applicants: ALCON RESEARCH, LTD., DHARMACON, INC.
    Inventors: Anja Smith, Angela Reynolds, Jon E. Chatterton, Xinyu Zhang